{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:54:44Z","timestamp":1791420884906,"version":"4.3.3"},"reference-count":85,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,11,13]],"date-time":"2002-11-13T00:00:00Z","timestamp":1037145600000},"content-version":"vor","delay-in-days":43,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunological Reviews"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:p><jats:bold>Summary:<\/jats:bold> A large set of peptide antigens presented by class I major histocompatibility complex (MHC) molecules on human and murine melanomas and recognized by CD8<jats:sup>+<\/jats:sup> T cells have been defined. These peptides represent attractive candidates for the development of therapeutic and\/or prophylactic approaches to treat this cancer. However, the majority of the peptides that are presented by multiple tumors and recognized by T cells from multiple patients arise from proteins that are also expressed in normal melanocytes. It is expected that immune responses to such peptides will be compromised by self\u2010tolerance or, alternatively, that stimulation of effective immune responses will be accompanied by autoimmune vitiligo. In this review, we describe a preclinical model to evaluate these issues and recent data to suggest that tolerance can be overcome to generate effective antitumor responses. This model also allows the rapid and systematic examination of parameters for the effective use of synthetic peptide vaccines.<\/jats:p>","DOI":"10.1034\/j.1600-065x.2002.18812.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T02:35:09Z","timestamp":1047436509000},"page":"136-146","source":"Crossref","is-referenced-by-count":95,"title":["Antigens derived from melanocyte differentiation proteins: self\u2010tolerance, autoimmunity, and use for cancer immunotherapy"],"prefix":"10.1111","volume":"188","author":[{"given":"Victor H.","family":"Engelhard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy N. J.","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa A.","family":"Colella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey L.","family":"Sheasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,11,13]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812223192527"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.2.489"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910570320"},{"key":"e_1_2_9_5_2","first-page":"3124","article-title":"Recognition of tyrosinase by tumor\u2010infiltrating lymphocytes from a patient responding to immunotherapy","volume":"54","author":"Robbins PF","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.2.527"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830260135"},{"key":"e_1_2_9_8_2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4049\/jimmunol.160.5.2099","article-title":"Human melanoma patients recognize an HLA\u2010A1\u2010restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development","volume":"160","author":"Kittlesen DJ","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7513441"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.3.1005"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.154.8.3961"},{"key":"e_1_2_9_12_2","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.4049\/jimmunol.157.11.5027","article-title":"Shared epitopes for HLA\u2010A3 restricted melanoma reactive human CTL include a naturally processed epitope from Pmel\u201017\/gp100","volume":"157","author":"Skipper JCA","year":"1996","journal-title":"J Immunol"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19981109)78:4<518::AID-IJC20>3.0.CO;2-0"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990827)82:5<669::AID-IJC9>3.0.CO;2-#"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.1.347"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.1.363"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.2.799"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.6.2207"},{"key":"e_1_2_9_19_2","first-page":"4895","article-title":"Identification of a shared HLA\u2010A*0201\u2010restricted T\u2010cell epitope from the melanoma antigen tyrosinase\u2010related protein 2 (TRP2)","volume":"58","author":"Parkhurst MR","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20000715)87:2<241::AID-IJC15>3.0.CO;2-L"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.3.453"},{"key":"e_1_2_9_22_2","first-page":"316","article-title":"Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay","volume":"4","author":"Pass HA","year":"1998","journal-title":"Cancer J Sci Am"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0398-328"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0398-321"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(20000515)86:4<538::AID-IJC16>3.0.CO;2-G"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(83)70182-9"},{"key":"e_1_2_9_27_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/archderm.1987.01660320095019","article-title":"Prognostic significance of hypopigmentation in malignant melanoma","volume":"123","author":"Bystryn J\u2010C","year":"1987","journal-title":"Arch Dermatol"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199601000-00009"},{"key":"e_1_2_9_29_2","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.4049\/jimmunol.157.6.2539","article-title":"Improved induction of melanoma\u2010reactive CTL with peptides from the melanoma antigen gp100 modified at HLA\u2010A*0201\u2010binding residues","volume":"157","author":"Parkhurst MR","year":"1996","journal-title":"J Immunol"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.4.1750"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00820664"},{"key":"e_1_2_9_32_2","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.4049\/jimmunol.158.12.5797","article-title":"A naturally processed peptide presented by HLA\u2010A*0201 is expressed at low abundance and recognized by an alloreactive CD8+ cytotoxic T cell with apparent high affinity","volume":"158","author":"Wang W","year":"1997","journal-title":"J Immunol"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300668"},{"key":"e_1_2_9_34_2","first-page":"6995","article-title":"Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model","volume":"60","author":"Schreurs MW","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_9_35_2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4049\/jimmunol.156.2.700","article-title":"Antigen\u2010specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy","volume":"156","author":"Zhai Y","year":"1996","journal-title":"J Immunol"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200001000-00008"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.2.277"},{"key":"e_1_2_9_38_2","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.4049\/jimmunol.156.7.2473","article-title":"Importance of MHC class I \u03b12 and \u03b13 domains in the recognition of self and non\u2010self MHC molecules","volume":"156","author":"Newberg MH","year":"1996","journal-title":"J Immunol"},{"key":"e_1_2_9_39_2","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4049\/jimmunol.146.4.1226","article-title":"Influenza A specific, HLA\u2010A2.1 restricted cytotoxic T lymphocytes from HLA\u2010A2.1 transgenic mice recognize fragments of the M1 protein","volume":"146","author":"Engelhard VH","year":"1991","journal-title":"J Immunol"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.173.4.1007"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/7.4.597"},{"key":"e_1_2_9_42_2","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.4049\/jimmunol.154.6.2733","article-title":"CTL responses of HLA\u2010A2.1\u2010transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA\u2010A2.1","volume":"154","author":"Shirai M","year":"1995","journal-title":"J Immunol"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/8.5.651"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830260115"},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.7.1221"},{"key":"e_1_2_9_46_2","first-page":"S272","article-title":"Direct identification of human tumor\u2010associated peptide antigens and a preclinical model to evaluate their use","volume":"6","author":"Engelhard VH","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"e_1_2_9_47_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.9.4853"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/0027-5107(93)90184-H"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1996.0012t.x"},{"key":"e_1_2_9_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0749.1993.tb00622.x"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.5.2354"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.10.5824"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199701000-00002"},{"key":"e_1_2_9_54_2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4049\/jimmunol.163.2.699","article-title":"Induction of anti\u2010tumor immunity using dendritic cells transduced with adenovirus vector\u2010encoding endogenous tumor\u2010associated antigens","volume":"163","author":"Kaplan JM","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_9_55_2","first-page":"253","article-title":"Genetic vaccination with \u201cself\u201d tyrosinase\u2010related protein 2 causes melanoma eradication but not vitiligo","volume":"60","author":"Bronte V","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_9_56_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.4.481"},{"key":"e_1_2_9_57_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.5.2651"},{"key":"e_1_2_9_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<89::AID-IJC14>3.0.CO;2-I"},{"key":"e_1_2_9_59_2","doi-asserted-by":"publisher","DOI":"10.1089\/10430340152710540"},{"key":"e_1_2_9_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700260"},{"key":"e_1_2_9_61_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.2.519"},{"key":"e_1_2_9_62_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.166.1.182"},{"key":"e_1_2_9_63_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.1.255"},{"key":"e_1_2_9_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1295-1297"},{"key":"e_1_2_9_65_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.1.283"},{"key":"e_1_2_9_66_2","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1996.0140"},{"key":"e_1_2_9_67_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.1.87"},{"key":"e_1_2_9_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970317)70:6<706::AID-IJC13>3.0.CO;2-7"},{"key":"e_1_2_9_69_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.17.8078"},{"key":"e_1_2_9_70_2","first-page":"2479","article-title":"Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE\u20101 peptide loaded antigen presenting cell\u2010based vaccine","volume":"56","author":"Hu X","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_9_71_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200007000-00013"},{"key":"e_1_2_9_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1323"},{"key":"e_1_2_9_73_2","first-page":"6451","article-title":"Immune and clinical responses in patients with metastatic melanoma to CD34 (+) progenitor\u2010derived dendritic cell vaccine","volume":"61","author":"Banchereau J","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_9_74_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.2.485"},{"key":"e_1_2_9_75_2","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.4049\/jimmunol.158.8.3593","article-title":"A tumor\u2010associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL\u201012 can prevent or revert the anergic state","volume":"158","author":"Grohmann U","year":"1997","journal-title":"J Immunol"},{"key":"e_1_2_9_76_2","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.4049\/jimmunol.160.9.4449","article-title":"Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells","volume":"160","author":"Toes RE","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_9_77_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.9.4102"},{"key":"e_1_2_9_78_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.2.989"},{"key":"e_1_2_9_79_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.5.2577"},{"key":"e_1_2_9_80_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.11.1637"},{"key":"e_1_2_9_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970127)70:3<302::AID-IJC10>3.0.CO;2-H"},{"key":"e_1_2_9_82_2","first-page":"859","article-title":"Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP\u20102","volume":"61","author":"Mendiratta SK","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_9_83_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.6.1203"},{"key":"e_1_2_9_84_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.6.2982"},{"key":"e_1_2_9_85_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.3.355"},{"key":"e_1_2_9_86_2","first-page":"2618","article-title":"Enhancement of tumor lysate\u2010 and peptide\u2010pulsed dendritic cell\u2010based vaccines by the addition of foreign helper protein","volume":"61","author":"Shimizu K","year":"2001","journal-title":"Cancer Res"}],"container-title":["Immunological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-065X.2002.18812.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-065X.2002.18812.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-065X.2002.18812.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T01:30:00Z","timestamp":1697506200000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-065X.2002.18812.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1034\/j.1600-065X.2002.18812.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-065x.2002.18812.x","archive":["Portico"],"relation":{},"ISSN":["0105-2896","1600-065X"],"issn-type":[{"value":"0105-2896","type":"print"},{"value":"1600-065X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}